ATL-1102 is under clinical development by Antisense Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ATL-1102’s likelihood of approval (LoA) and phase transition for Duchenne Muscular Dystrophy took place on 04 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ATL-1102 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ATL-1102 overview

ATL-1102, (TV-1102, ISIS 107248) is under development for the treatment of relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, acute myeloid leukemia, asthma and Duchenne muscular dystrophy and limb girdle muscular dystrophy R2. It is administered through subcutaneous, inhalation route of administration. It is formulated as a solution for multiple sclerosis.  ATL1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (very late antigen-4). The therapeutic candidate is developed based on antisense technology. It was also under development for the treatment of hematopoietic stem cell transplantation.

Antisense Therapeutics overview

Antisense Therapeutics is clinical staged biopharmaceutical company which focuses on the discovery, development, and commercialization of second-generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on the development of antisense drugs in the areas of immunology disorders and rare diseases such as multiple sclerosis (MS) among others. Antisense Therapeutics’s development pipeline comprises of ATL1103 for potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being development for the treatment of multiple sclerosis. ATL1102 is also being developed for the treatment of duchenne muscular dystrophy (DMD). Antisense Therapeutics is headquartered in Toorak, Victoria, Australia.

Quick View ATL-1102 LOA Data

Report Segments
  • Innovator
Drug Name
  • ATL-1102
Administration Pathway
  • Inhalational
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Immunology
  • Musculoskeletal Disorders
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.